O	0	7	Effects
O	8	10	of
B-intervention	11	19	physical
I-intervention	20	28	exercise
O	29	31	on
O	32	39	markers
O	40	42	of
O	43	55	inflammation
O	56	58	in
O	59	65	breast
O	66	72	cancer
O	73	81	patients
O	82	88	during
O	89	97	adjuvant
O	98	110	chemotherapy
O	110	111	.

O	112	120	Exercise
O	121	124	has
O	125	129	been
O	130	135	shown
O	136	138	to
O	139	145	reduce
O	146	153	fatigue
O	154	160	during
O	161	167	cancer
O	168	177	treatment
O	177	178	.

O	179	191	Hypothesized
O	192	202	mechanisms
O	203	210	include
O	211	223	inflammatory
O	224	232	pathways
O	232	233	.

O	234	243	Therefore
O	243	244	,
O	245	247	we
O	248	260	investigated
O	261	268	effects
O	269	271	of
O	272	280	exercise
O	281	283	on
O	284	291	markers
O	292	294	of
O	295	307	inflammation
O	308	310	in
O	311	317	breast
O	318	324	cancer
O	325	333	patients
O	334	340	during
O	341	349	adjuvant
O	350	362	chemotherapy
O	362	363	.

O	364	366	We
O	367	373	pooled
O	374	378	data
O	379	383	from
O	384	387	two
O	388	398	randomized
O	399	409	controlled
O	410	418	exercise
O	419	431	intervention
O	432	438	trials
O	439	443	with
B-eligibility	444	450	breast
I-eligibility	451	457	cancer
I-eligibility	458	466	patients
I-eligibility	467	473	during
I-eligibility	474	482	adjuvant
I-eligibility	483	495	chemotherapy
O	496	497	(
O	497	498	n
O	499	500	=
B-total-participants	501	504	130
O	504	505	)
O	505	506	,
O	507	512	which
O	513	516	had
O	517	527	previously
O	528	533	shown
O	534	544	beneficial
O	545	552	effects
O	553	555	of
O	556	564	exercise
O	565	567	on
O	568	575	fatigue
O	575	576	.

O	577	585	Exercise
O	586	595	comprised
O	596	597	a
O	598	600	12
O	600	601	-
O	601	605	week
O	606	616	resistance
O	617	625	training
O	626	627	(
O	627	632	BEATE
O	633	638	study
O	638	639	)
O	640	642	or
O	643	645	an
O	646	648	18
O	648	649	-
O	649	653	week
O	654	662	combined
O	663	673	resistance
O	674	677	and
O	678	685	aerobic
O	686	694	training
O	695	696	(
O	696	700	PACT
O	701	706	study
O	706	707	)
O	707	708	.

O	709	714	Serum
O	715	717	IL
O	717	718	-
O	718	719	6
O	719	720	,
O	721	723	IL
O	723	724	-
O	724	727	1ra
O	727	728	,
O	729	732	and
O	733	736	the
O	737	739	IL
O	739	740	-
O	740	741	6
O	741	742	/
O	742	744	IL
O	744	745	-
O	745	748	1ra
O	749	754	ratio
O	755	759	were
O	760	770	quantified
O	771	773	at
O	774	782	baseline
O	782	783	,
O	784	787	mid
O	787	788	-
O	788	800	intervention
O	800	801	,
O	802	806	post
O	806	807	-
O	807	819	intervention
O	819	820	,
O	821	824	and
O	825	826	6
O	826	827	-
O	827	828	9
O	829	835	months
O	836	840	post
O	840	841	-
O	841	849	baseline
O	849	850	.

O	851	856	Mixed
O	857	863	effect
O	864	870	models
O	871	877	showed
O	878	889	significant
O	890	899	increases
O	900	902	in
B-outcome	903	905	IL
I-outcome	905	906	-
I-outcome	906	907	6
I-outcome	908	911	and
I-outcome	912	914	IL
I-outcome	914	915	-
I-outcome	915	916	6
I-outcome	916	917	/
I-outcome	917	919	IL
I-outcome	919	920	-
I-outcome	920	923	1ra
I-outcome	924	929	ratio
O	930	936	during
O	937	949	chemotherapy
O	950	953	and
O	954	963	decreases
O	964	974	afterwards
O	974	975	.

O	976	987	Differences
O	988	995	between
O	996	1004	exercise
O	1005	1008	and
O	1009	1016	control
O	1017	1022	group
O	1023	1027	were
O	1028	1031	not
O	1032	1043	significant
O	1044	1046	at
O	1047	1050	any
O	1051	1055	time
O	1056	1061	point
O	1061	1062	.

O	1063	1070	Changes
O	1071	1073	in
O	1074	1079	total
B-outcome	1080	1086	cancer
I-outcome	1086	1087	-
I-outcome	1087	1094	related
I-outcome	1095	1102	fatigue
O	1103	1107	were
O	1108	1121	significantly
O	1122	1132	correlated
O	1133	1137	with
O	1138	1145	changes
O	1146	1148	in
O	1149	1151	IL
O	1151	1152	-
O	1152	1153	6
O	1153	1154	/
O	1154	1156	IL
O	1156	1157	-
O	1157	1160	1ra
O	1161	1166	ratio
O	1167	1168	(
O	1168	1175	partial
O	1176	1187	correlation
O	1188	1189	r
O	1190	1191	=
O	1192	1193	0
O	1193	1194	.
O	1194	1196	23
O	1196	1197	)
O	1198	1201	and
O	1202	1204	IL
O	1204	1205	-
O	1205	1206	6
O	1207	1208	(
O	1208	1209	r
O	1210	1211	=
O	1212	1213	0
O	1213	1214	.
O	1214	1216	21
O	1216	1217	)
O	1217	1218	,
O	1219	1222	and
O	1223	1230	changes
O	1231	1233	in
O	1234	1242	physical
O	1243	1249	cancer
O	1249	1250	-
O	1250	1257	related
O	1258	1265	fatigue
O	1266	1270	with
O	1271	1278	changes
O	1279	1281	in
O	1282	1284	IL
O	1284	1285	-
O	1285	1286	6
O	1286	1287	/
O	1287	1289	IL
O	1289	1290	-
O	1290	1293	1ra
O	1294	1299	ratio
O	1300	1301	(
O	1301	1302	r
O	1303	1304	=
O	1305	1306	0
O	1306	1307	.
O	1307	1309	21
O	1309	1310	)
O	1310	1311	.

B-outcome	1312	1319	Changes
I-outcome	1320	1322	in
I-outcome	1323	1330	fatigue
O	1331	1335	were
O	1336	1344	slightly
O	1345	1355	correlated
O	1356	1360	with
B-outcome	1361	1368	changes
I-outcome	1369	1371	in
I-outcome	1372	1384	inflammatory
I-outcome	1385	1392	markers
O	1392	1393	,
O	1394	1397	and
O	1398	1403	there
O	1404	1407	was
O	1408	1409	a
O	1410	1416	strong
O	1417	1429	inflammatory
O	1430	1438	response
O	1439	1441	to
O	1442	1450	adjuvant
O	1451	1463	chemotherapy
O	1463	1464	.

O	1465	1468	The
O	1469	1479	supervised
O	1480	1488	exercise
O	1489	1497	training
O	1498	1501	did
O	1502	1505	not
O	1506	1516	counteract
O	1517	1521	this
O	1522	1530	increase
O	1531	1533	in
O	1534	1546	inflammation
O	1546	1547	,
O	1548	1558	suggesting
O	1559	1563	that
O	1564	1574	beneficial
O	1575	1582	effects
O	1583	1585	of
O	1586	1594	exercise
O	1595	1597	on
O	1598	1605	fatigue
O	1606	1612	during
O	1613	1621	adjuvant
O	1622	1634	chemotherapy
O	1635	1638	for
O	1639	1645	breast
O	1646	1652	cancer
O	1653	1656	are
O	1657	1660	not
O	1661	1672	essentially
O	1673	1681	mediated
O	1682	1684	by
O	1685	1687	IL
O	1687	1688	-
O	1688	1689	6
O	1689	1690	,
O	1691	1693	IL
O	1693	1694	-
O	1694	1697	1ra
O	1697	1698	,
O	1699	1701	or
O	1702	1705	the
O	1706	1708	IL
O	1708	1709	-
O	1709	1710	6
O	1710	1711	/
O	1711	1713	IL
O	1713	1714	-
O	1714	1717	1ra
O	1718	1723	ratio
O	1723	1724	.
